Inventiva S.A. (NASDAQ:IVA - Get Free Report) shares fell 6% on Monday . The company traded as low as $2.15 and last traded at $2.21. 9,217 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 70,537 shares. The stock had previously closed at $2.35.
Wall Street Analyst Weigh In
Several brokerages have issued reports on IVA. Stifel Nicolaus cut their price objective on shares of Inventiva from $20.00 to $17.00 and set a "buy" rating for the company in a research report on Friday, November 22nd. UBS Group assumed coverage on Inventiva in a research note on Tuesday, November 12th. They issued a "neutral" rating and a $3.00 price target for the company. Finally, HC Wainwright lowered their price objective on Inventiva from $14.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, October 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Inventiva has a consensus rating of "Moderate Buy" and an average target price of $13.25.
Get Our Latest Stock Analysis on IVA
Inventiva Trading Down 0.5 %
The company's fifty day moving average price is $2.61 and its 200 day moving average price is $2.48.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
See Also
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
